Ekuinas Acquires Strategic Minority Stake in Ain Medicare to Fuel Malaysia Pharma Expansion

Ekuiti Nasional Berhad (Ekuinas) has secured a strategic minority stake in Ain Medicare Sdn Bhd, bolstering Malaysia's homegrown pharmaceutical capabilities.

The investment draws from Ekuinas' MYR 1 billion Tranche IV fund, targeting scalable enterprises in priority sectors.

Ain Medicare's Proven Legacy

Established in 1993 in Kota Bharu, Kelantan, Ain Medicare has built a 30-year track record as a leader in sterile parenteral products including injectables and IV solutions.

The firm employs about 1,400 primarily Bumiputera staff and exports to 17 countries while nurturing over 100 local SMEs through vendor programs.

Prior support from VentureTECH since 2017 enhanced its manufacturing scale and operations.

Ekuinas' Strategic Mandate

As part of the Permodalan Nasional Berhad ecosystem, Ekuinas focuses on elevating Bumiputera firms in healthcare for national economic resilience.

This deal exemplifies the 'Bumiputera Relay Race' model, mirroring success with Orkim Berhad through phased institutional backing.

Impact and Future Horizons

The partnership will accelerate Ain Medicare's push into specialized generics, advanced injectables, and broader international markets.

Industry leaders praise the move for fostering innovation, regulatory strength, and export growth in pharmaceuticals.

Malaysia's pharmaceuticals industry eyes 6.4% annual growth to exceed MYR 15 billion by 2030 amid rising healthcare demands.

Overall, this alliance promises enhanced self-sufficiency and competitiveness for Malaysian pharma on the global stage.